EVAX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of --. Evaxion Biotech AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 911.45%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 185.08%. Given that Evaxion Biotech AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion Biotech AS is more attractive than DBV Technologies SA.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion Biotech AS's net income of -$1.9M is higher than DBV Technologies SA's net income of -$23M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.42x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -9.55%. Evaxion Biotech AS's return on equity of -- beat Edap TMS SA's return on equity of -39.5%.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 911.45%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 548.86%. Given that Evaxion Biotech AS has higher upside potential than Edap TMS SA, analysts believe Evaxion Biotech AS is more attractive than Edap TMS SA.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.615%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Edap TMS SA quarterly revenues of $21.7M. Evaxion Biotech AS's net income of -$1.9M is higher than Edap TMS SA's net income of -$2.1M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.42x versus 0.71x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of 32.95%. Evaxion Biotech AS's return on equity of -- beat Novo Nordisk AS's return on equity of 86.85%.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 911.45%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.21 which suggests that it could grow by 68.91%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.57% to investors and pays a quarterly dividend of $1.10 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Evaxion Biotech AS's net income of -$1.9M is lower than Novo Nordisk AS's net income of $4B. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.42x versus 6.67x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -31.41%. Evaxion Biotech AS's return on equity of -- beat Trinity Biotech PLC's return on equity of --.

Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 911.45%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2677.78%. Given that Trinity Biotech PLC has higher upside potential than Evaxion Biotech AS, analysts believe Trinity Biotech PLC is more attractive than Evaxion Biotech AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 20.986%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Trinity Biotech PLC quarterly revenues of $15.2M. Evaxion Biotech AS's net income of -$1.9M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.42x versus 0.10x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.